|
|
| |
 |
|
|
 |
|
KRAS Testing is Essential to Anti-EGFR Therapy
|
 |
KRAS Testing is Essential Prior to Anti-EGFR Therapy. The anti-EGFR antibodies show activity in multiple tumor types. However, responses are seen only in the subset of patients lacking a KRAS mutation (wild-type KRAS).
Wild-type KRAS is Required for Monotherapy Efficacy
- Results from pivotal "408" trial demonstrate panitumumab monotherapy was signifi cantly more effective than best supportive care in treating mCRC patients.
- The treatment effect on progression-free survival (PFS) in the wild-type KRAS group was signifi cantly greater than in the mutant group.
- Response rates to panitumumab were much greater (17% vs. 0%) for the wild-type group. Wild-type KRAS patients also had longer overall survival.
 
Wild-type KRAS is Required for Combination Therapy Efficacy
- CRYSTAL was a Phase III study in first-line mCRC which compared cetuximab plus FOLFIRI to FOLFIRI alone. The results of this study also noted the KRAS mutation status for the enrolled patient.
- Anti-EGFR shows additional PFS benefit in patients with wild-type KRAS in CRC as first-line treatment in combination with chemotherapy.
  |
|
|
 |
|
 |
|
|
|
|
|
| |
|